Title:
BISPECIFIC ANTIBODY INCLUDING FIRST ANTIGEN-BINDING SITE THAT SPECIFICALLY BINDS TO HUMAN ANGIOPOIETIN-2, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/085606
Kind Code:
A1
Abstract:
The present invention relates to a bispecific antibody including a first antigen-binding site that specifically binds to human angiopoietin-2 (ANG-2), and a second antigen-binding site that specifically binds to at least one antigen selected from the group consisting of human vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta, T-cell immunoglobulin and mucin domain-containing protein (TIM)-3 ligand, and pigment epithelium-derived factor receptor (PEDF-R), wherein the first antigen-binding site that specifically binds to the ANG-2 includes, in the heavy chain variable domain, a CDRH1 region of SEQ ID NO: 1 or 7 or 13, a CDRH2 region of SEQ ID NO: 2 or 8 or 14, and a CDRH3 region of SEQ ID NO: 3 or 9 or 15, and includes, in the light chain variable domain, a CDRL1 region of SEQ ID NO: 4 or 10 or 16, a CDRL2 region of SEQ ID NO: 5 or 11 or 17, and a CDRL3 region of SEQ ID NO: 6 or 12 or 18.
Inventors:
KIM YONG IN (KR)
OH IN JAE (KR)
KIM HEE GON (KR)
KIM YEA JIN (KR)
OH IN JAE (KR)
KIM HEE GON (KR)
KIM YEA JIN (KR)
Application Number:
PCT/KR2023/016063
Publication Date:
April 25, 2024
Filing Date:
October 17, 2023
Export Citation:
Assignee:
NEORTESBIO INC (KR)
International Classes:
C07K16/22; A61K39/00; C07K16/28
Domestic Patent References:
| WO2022212360A1 | 2022-10-06 |
Foreign References:
| KR20190039577A | 2019-04-12 | |||
| US20220073599A1 | 2022-03-10 | |||
| US20210324062A1 | 2021-10-21 | |||
| US20150079112A1 | 2015-03-19 |
Attorney, Agent or Firm:
KOO, Hyun Seo (KR)
Download PDF: